
Immunological aspects in diabetes patients

Mihai G. Netea



Diabetes increase between 2017 and 2045




Source: IDF Diabetes Atlas, 2017; http://www.diabetesatlas.org/


Are diabetes patients more susceptible to infections?

Some relatively rare infections almost exclusively in DM patients

Rhinocerebral mucormycosis (fungal infection)







Hemotoxylin and Eosin stain (necrosis, PMNs, hyphae)

Rhino-orbital mucormycosis emerging in tropics



India, 12 years diabetes, dropped from care. HbA1c 11%

Singh Bakshi, Lancet DM 2016

- India, Africa, Mexico
- Often first presentation of diabetes
- 6-fold increase in last 20 years
- Diagnostic & therapeutic challenge (e.g. no Amph B or surgery)
- High mortality
- Other invasive fungal infections also emerging (e.g. Aspergillus)

Bhansali, PostGrad Med 2009


Other 'DM-specific' infections


Klebsiella pneumoniae liver abscess: a new invasive syndrome

L Kristopher Siu, Kuo-Ming Yeh, Jung-Chung Lin, Chang-Phone Fung, Feng-Yee Chang

Klebsiella pneumoniae is a well known human nosocomial pathogen. Most community-acquired K pneumoniae infections cause pneumonia or urinary tract infections. During the past two decades, however, a distinct invasive syndrome that causes liver abscesses has been increasingly reported in Asia, and this syndrome is emerging as a global disease. In this Review, we summarise the clinical presentation and management as well the microbiological aspects of this invasive disease. Diabetes mellitus and two specific capsular types in the bacterium predispose a patient to the development of liver abscesses and the following metastatic complications: bacteraemia, meningitis, endophthalmitis, and necrotising fasciitis. For patients with this invasive syndrome, appropriate antimicrobial treatment combined with percutaneous drainage of liver abscesses increases their chances of survival. Rapid detection of the hypervirulent strain that causes this syndrome allows earlier diagnosis and treatment, thus minimising the occurrence of sequelae and improving clinical outcomes.

Extensive extra-hepatic lesions: CNS infections, necrotising fasciitis, endophtalmitis etc








Fournier's gangrene



Specific capsular types Loss of 'string test'

Mellioidosis



- Severe disease caused by *Burkholderia pseudomallei*
- Sepsis, pneumonia, abscesses
- Particularly in South-East Asia
- 40-60% of patients have DM

More common infections

- Candida (muco-cutaneous and invasive)
- Bacterial pneumonia
- Urinary tract infections
- Skin- and soft-tissue infections
- Eye infections
- Bloodstream infections (bacteremia)
- More common, often more severe
- More and longer hospital admission
- Increased risk of amputation after necrotising limb infections
- More metastatic infections (e.g. endophtalmitis in candidemia)

DM is associated with active TB

Author, year	Country	Population	TB cases		Estimate (95% CI)
Prospective (RR, HR) Cegielski JP., 2012 Kim SJ., 1995 John GT., 2001 Leung CC., 2008 Pooled estimate (I-squared =	USA South Korea India China 77.9%, p = 0.004)	14189 814713 1251 42116	61 5105 166 326	+++	7.58 (2.94, 19.49) 4.97 (3.68, 6.70) 2.24 (1.38, 3.65) 2.69 (1.94, 3.72) 3.59 (2.25, 5.73)

- 44 studies from 16 countries
- Prospective: DM ~ 3.6-fold higher TB risk (2.3-5.7)
- Higher in low-income and high-incidence
- Higher in Asia compared to Europe/USA
- Higher for confirmed TB and blood tested DM
- DM accounts for 11% (Nigeria) to 18% (India) of TB in high burden countries

Al-Rifai, Pearson, Critchley, Abu-Raddad. Plos One 2017

Ou SM, 2012 Taiwan 4554 109 1,42 1,59 1,50						(, -
Suvarpindkul G. 2014 USA 5162 791 Ou SM. 2012 Tahan 4554 109 Runguanghiranya S. 2008 Thaland 233 9 Pooled estimate (I-squared = 0.0%, p = 0.391) Retrospective (RRs, RR, HR) Pering L. 2015 UK 694 1000 969 Mu CY. 2011 Taiwan 28455 694 Kumper-Jorgensen Z. 2015 Demark 77935 6468 Hu HY. 2014 Taiwan 20655 287 Charge J. 2014 Taiwan 2055 59 Shen TC. 2014 Taiwan 25975 59 Shen K. 2013 Taiwan 756 29 Moran-Miendoza O. 2010 Canada 33146 228 Dobler CC. 2012 Australia 1965(238) 6276 Demorw SE. 2015 USA 2779100 6050 Cher W. 2013 Taiwan 70782 1228 Pooled estimate (I-squared = 77.1%, p = 0.000) Cross-sectional (OR) Cross-sectional (OR) Cross-sectional (OR) Pational 1986 133 Calebarder A. 2014 USA 2579 Pooled estimate (I-squared = 28.9%, p = 0.245) Case-controt (OR) Pational 28349 5556 Coker R. 2005 Russia 334 134 Pooled estimate (I-squared = 28.9%, p = 0.245) Case-controt (OR) Pational Lasson 334 Statistica 334 134 Pooled estimate (I-squared = 28.9%, p = 0.245) Case-controt (OR) Pational Contain 334 Statistica 334 134 Pooled estimate (I-squared = 28.9%, p = 0.245) Case-controt (OR) Pational Contain 334 Statistica 334 Pooled estimate (I-squared = 28.9%, p = 0.245) Case-controt (OR) Pational Statistica 334 Statistica 334	D					I.	
Ou SM, 2012 Taiwan 4554 109 Reprosang/Impass 233 9 Pooled estimate (I-squared = 0.0%, p = 0.391) 233 9 Retrospactive (RRs, RR, HR) 233 9 Pealing L, 2015 UK 694 1000 969 Wol CY, 2011 Taiwan 82435 694 Kamper-Jorgensen Z, 2015 Demmark 77835 6468 Chung WS, 2014 Taiwan 50840 106168 Baker MA, 2012 Taiwan 25349 5013 Shen TC, 2014 Taiwan 25349 5013 Shen TC, 2014 Taiwan 25349 5013 Shen TC, 2014 Taiwan 25383 6276 Chen CH, 2006 Taiwan 2797000 6650 Demore SE, 2015 USA 2797000 6650 Demore SE, 2015 USA 103050 668 Young P, 2012 England 83739 7966 Pooled estimate (I-squared = 28.9%, p = 0.245) 1.30(11.0% Casse-control (OR)		1104	6400	704			4 04 /4 07
Runguraghiranya S. 2008 Thailand 233 9 Pooled estimate (I-squared = 0.0%, p = 0.391) 359 (0.74) Pealing L. 2015 UK 6041000 Pealing L. 2015 UK 6041000 Wu CY, 2011 Talwan 82435 Fursynet/We CRS, RR, HR) Talwan 20855 Chung NS, 2014 Talwan 20855 Chung NS, 2014 Talwan 25349 Ston IC, 2014 Talwan 25349 Ston IC, 2014 Talwan 25375 Shen TC, 2014 Talwan 25375 Shen TC, 2014 Talwan 25375 Chen W, 2013 China 177529 Chen W, 2013 Canada 33146 Dokler CC, 2012 Australia 1995233 Dobler CC, 2012 Australia 1995236 Dobler CC, 2013 Talwan 10057 Coss-sectional (OR) Teams Centerk Coss-sectional (OR) Teams Centerk Case-control (OR) Teams Centerk Case-control (OR) USA 334 Case-control (OR) Teams Centerk Case-control (OR) USA 303 Case-control (OR) USA 334							
Profed estimate (I-squared = 0.0%, p = 0.391) 1.69 (1.3) Ratrospective (RPs, RR, HR) Preaing L. 2015 UK 6041000 969 Worl CV, 2011 Talwan 52045 634 1.30 (1.04) Kamper-Lorgensen Z, 2015 Demmark 77835 6468 1.00 (1.43) Much V, 2014 Talwan 50265 287 1.30 (1.04) Shert MA, 2012 Talwan 50265 287 1.30 (1.04) Shert MA, 2012 Talwan 50265 287 1.30 (1.04) Shert MA, 2012 Talwan 253349 5013 556 Chen CH, 2006 Talwan 252975 59 4.43 (2.43) 0.24 (3.02,44) Chen CH, 2006 Talwan 70752 117 56 29 3.07 (1.14) 1.49 (1.05) Demlow SE, 2015 USA 2797000 6650 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) 1.49 (1.05) <td></td> <td></td> <td></td> <td></td> <td></td> <td>- ·</td> <td></td>						- ·	
Retrospective (RRs, RR, HR) UK 6941000 969 Pealing L, 2015 UK 6941000 969 Wu GY, 2011 Taiwan 82435 694 Kampen-Jorgensen Z, 2015 Demmark 77935 6468 Mu HY, 2014 Taiwan 20855 287 Chung WS, 2014 Taiwan 25915 513 Shen TC, 2014 Taiwan 25915 59 Chen W, 2013 Taiwan 25915 59 Chen W, 2013 Taiwan 25915 59 Chen W, 2013 Taiwan 756 29 Moran-Menocaz O, 2010 Canada 791673 1118 Dokler CC, 2012 Australial 19955283 6276 Denicow SE, 2015 USA 27797000 6362 Pooled estimate (I-squared = 77.1%, p = 0.000) 10557 6382 Cross-sectional (OR) Rearks Canteria Raish A. 2011 USA 3344 535 Cords-Az, 2014 USA 5290 37366 <t< td=""><td></td><td></td><td>233</td><td>9</td><td></td><td></td><td></td></t<>			233	9			
Pealing L, 2015 UK 6941000 969 1.30 (1.04) Wu CV, 2011 Taiwan 82435 694 1.38 (1.17) Kampor-Jorgensen Z, 2015 Dermark 77935 6468 1.60 (1.43) Hu HY, 2014 Taiwan 50840 10168 1.38 (1.17) Bater MA, 2012 Taiwan 25375 59 2.60 (1.34) 1.31 (1.23) Shen TC, 2014 Taiwan 25975 59 2.60 (1.34) 1.31 (1.23) Shen TC, 2014 Taiwan 25975 59 1.37 (1.14) 2.43 (0.24) Chen W, 2013 China T17529 117 2.43 (0.24) 1.76 (0.14) Chen K, 2007 Canada 73144 2.28 (1.24) 1.76 (0.24) 1.83 (1.17) Mora-Mendoza O, 2010 Canada 771700 6502 1.25 (1.02) 1.26 (1.02) Cobler CC, 2012 Australia 19955283 6275 1.49 (10.5) 1.49 (10.5) Cobler CC, 2013 Taiwan 70782 1228 1.05 (1.5) 1.25 (1.2)	Pooled estimate (I-squared =	0.0%, p = 0.391)			C		1.69 (1.3
Wu C7, 2011 Taiwan 82435 694 Kamper-Jogensen Z, 2015 Demmark 77935 6488 Hu HY, 2014 Taiwan 20855 287 Chang WS, 2014 Taiwan 50840 10168 Bater MA, 2012 Taiwan 50840 10168 Bater MA, 2012 Taiwan 253349 5013 Shan TC, 2013 Taiwan 253349 5013 Shan TC, 2013 Chana 177529 117 Atom Androzza 0,2010 Canada 33146 228 Denler OC, 2012 Australia 19855233 6276 116 Denler OC, 2012 Australia 19855233 6276 1.87 (10.0 Denler OC, 2012 Australia 1985523 6276 1.87 (10.0 Pooled estimate (I-squared = 27.1%, p = 0.000) 1.55 (1.31 1.55 (1.31 1.55 (1.31 Case-control (OR) Texas Centralia 1.3057 6382 Pooled estimate (I-squared = 28.9%, p = 0.245) 1.55 (1.31 1.70 (1.25) Case						i i	10330355
Kamper-Jorgensen Z, 2015 Demmark 77835 6468 (14.3) Hu HY, 2014 Telwan 20655 287 Chung WS, 2014 Telwan 150840 10168 (15.5) 147 Baker MA, 2012 Telwan 12735 57 Kito MC, 2013 Telwan 223348 5013 (13.1) 123 Shen TC, 2014 Telwan 223348 5013 (13.1) 123 Shen TC, 2014 Telwan 223348 5013 (13.1) 123 Chen W., 2013 China 177529 117 (14.1) 117529 (17.1) 117 Chen W., 2006 Telwan 756 23 Moran-Mendoza O, 2010 Canada 33148 228 (27.6) (14.2) (+		
Hu HY, 2014 Taiwan 20855 287 1.38 (105) Chung WS, 2014 Taiwan 20855 287 1.55 (147) Baker MA, 2012 Taiwan 25349 5013 1.55 (147) Baker MA, 2012 Taiwan 253349 5013 1.31 (123) Shem TC, 2014 Taiwan 25375 59 2.43 (024) Chen CH, 2006 Canada 3191673 1118 0.04 (176) 3.07 (114) Moran-Mendoza O, 2010 Canada 3191673 1118 0.00 (08) 0.00 (08) Dobler CC, 2012 Australia 19855233 6276 1.49 (105) 2.48 (179) Demolw SE, 2015 USA 27197000 6050 2.48 (179) 1.55 (1.3) Pooled estimate (I-squared = 28,9%, p = 0.260) Taiwan 70762 1.28 (102, 102) 1.55 (1.3) Case-control (OR) Texas Central 13057 632 70366 Aligibhana B, 2005 Indonesia 454 556 1.70 (1.23 (1.37, 114) 733 (1.37, 114) Center V, 20					•		
Chung WS, 2014 Taiwan 50840 10168 11715 57 Kito MC. 2013 Taiwan 253349 5013 57 Kito MC. 2013 Taiwan 253349 5013 57 Shen TC. 2014 Taiwan 253349 5013 57 Chen CH, 2006 Taiwan 756 29 MoranMiendoza O. 2010 Canada 33146 2975 59 Chen CH, 2007 Canada 791673 1118 1.76 (1254 1.76 (1254 1.76 (1254 1.76 (1254 1.76 (1254 1.76 (1254 1.77 (125 1.27 (125 1.25 (125					•		
Baker MA, 2012 Talwan 17715 57 Kuko MC, 2013 Talwan 25975 59 Chem W., 2014 Talwan 25975 59 Chem W., 2013 China 177529 117 Chem W., 2010 Canada 33146 228 Dobler CC, 2012 Australia 19855238 6276 Dobler CC, 2012 Australia 19855263 6276 Dobler CC, 2012 Australia 1995526 688 Pooled estimate (I-squared = 77.1%, p = 0.000) Cross-sectional (OR) Case-control (OR) Case-control (OR) Data SU, 2013 China 13057 6382 Pooled estimate (I-squared = 2.9%, p = 0.245) Case-control (OR) Data SU, 2013 China 13057 Case-control (OR) Duskin SE, 1994 USA 151 545 La SW, 2014 Talwan 11386 45464 Viney K. 2015 Republic of Kribati 275 499 Duskin SE, 1994 USA 151 545 La SW, 2014 USA 151 545 La SW, 2016 USA 148 220 Duskin SE, 1994 USA 151 545 La SW, 2016 USA 148 220 Duskin SE, 1994 USA 151 545 La SW, 2016 USA 148 220 Duskin SE, 1994 USA 151 545 La SW, 2016 USA 346 46 Pooled estimate (I-squared = 79.5%, p = 0.000) Talwan 224 438 Pooled estimate (I-squared = 79.5%, p = 0.000)					+		
Kuo MC. 2013 Taiwan 253349 5013 Shen TC. 2014 Taiwan 25975 59 Chen W. 2013 Dhna 177529 117 Chen K. 2016 Taiwan 25975 59 Chen K. 2017 Canada 77529 117 Moran-Mandoza O., 2010 Canada 791673 1118 Doher CC. 2012 Australial 19955283 6276 Demiow SE, 2015 USA 27797000 6560 Demiow SE, 2015 USA 27797000 6560 Conse-sectional (OR) England 837399 7996 Colose-sectional (OR) Conse-sectional (OR) 13057 6382 Coles estimate (I-squared = 28.9%, p = 0.245) 143 (13.7 Case-control (OR) Taixan 245 (13.2 Case-control (OR) Texas Central Case-control (OR) Taixan 245 (13.2 Case-control (OR) Taixan 245 (13.2 Case-control (OR) Taixan 245 (13.2 Case-control (OR) Taixa					•		
Shen TC. 2014 Taiwan 2597 59 Chen W., 2013 China 177529 117 Chen W., 2016 Taiwan 756 29 Moran-Miendoza O., 2010 Canada 33146 228 Dobler CC, 2012 Australia 19955238 6276 Demork SE, 2015 USA 27797000 6050 Lee CH., 2013 Taiwan 707822 1228 Young F, 2012 England 837399 7996 Pooled estimate (I-squared = 77.1%, p = 0.000) 13057 6382 Cross-sectional (OR) Goldhaber-Fiberal U.2011 46 countries Alsiphbna B, 2068 Indonesia 3454 Alsiphbna B, 2068 Indonesia 3454 Alsiphbna B, 2068 Russia 3347 Case-control (OR) Expandible Kinbasi 2450 Case-control (OR) Expandible Kinbasi 3454 Case-control (OR) Expandible Kinbasi 3454 Case-control (OR) Expandible Kinbasi 2450 Case-control (OR) Expandible						•	
Chen W., 2013 China 17752 117 43 (0.44) Chen CH., 2006 Talwan 7756 29 Dobler CC, 2012 Canada 33146 228 Dobler CC, 2012 Australia 19855283 6276 Dention SE, 2015 USA 27797000 6050 L49 (105 Dention SE, 2015 USA 27797000 6050 L49 (105 Dention SE, 2015 USA 27797000 6050 L49 (105 Coss-sectional (OR) Goldhaber-Fiebert JD, 2011 46 countries 124545 1744 Maris SM, 2011 USA 190350 668 Maris SM, 2011 USA 190350 668 Maris SM, 2011 USA 190350 668 Maris SM, 2006 Infonesia 454 556 Coter R, 2006 USA 1394 7366 Algolabar 28, 9%, p = 0.2451 Cotes control (OR) Cotes - 2006 USA 2347 66714 Fautoal-Agonto L32 Fautoal-Agont Domesia 454 556 Coter R, 2006 USA 110 Las Nu, 2011 USA 190350 1668 USA 3347 66714 Fautoal-Agont Domesia 454 556 Coter R, 2006 USA 110 Las Nu, 2017 Talwan 2550 14274 Las Nu, 2017 Talwan 2250 14274					٠	1000	1.31 (1.23,
Chen CH, 2006 Taiwan 756 29 Moran-Mendoz 0,2010 Canada 73146 228 Dyck RF, 2007 Canada 791673 1118 Dobler CC, 2012 Austalia 19855283 6276 Demorw SE, 2015 USA 27197000 6050 2.18 (1.79 Lee CH, 2013 Taiwan 70762 1228 Probled estimate (I-squared = 77.1%, p = 0.000) Cross-sectional (OR) Cross-sectional (OR) Cross-sectional (OR) Case-control (OR) Ca							4.23 (2.43,
Meran-Mendoza 0, 2010 Canada 33146 228 116 100 (0.84) Dobler CC, 2012 Australia 19855233 6276 144 (105) Denorkov SE, 2015 USA 2797000 6660 2.88 (174) Lee CH, 2013 Taiwan 70722 1228 1.25 (102) Cooss-sectional (OR) England 837399 7996 Cooss-sectional (OR) Taiwan 124545 1744 Maris SM, 2011 USA 190350 668 Variaris SM, 2011 USA 190350 668 Variaris SM, 2006 Infonesia 454 556 Corist V., 2015 USA 3347 66714 Fauthoh-Lepsen D., 2011 Tarxania 803 350 Carles V., 2015 Republic of Kinbas 275 498 Salt SM, 2014 Tarxania 300 3001 Jarcen-Sandowic A, 2013 Coratia 300 3001 1.80 (12, 174) Jarcen-Sandowic A, 2013 Creatia 300 3001 1.80 (12, 174)					+-	and the second s	2.43 (0.84,
Dpck RF, 2007 Canada 791673 1118 100 (0.6) Doubler CC, 2012 Australia 19955283 8276 1.49 (100 (0.6) Demice XE, 2015 USA 2797000 6050 2.18 (1.7) 1.49 (152 (1.2) Lee CH, 2013 Taiwan 70782 1228 1.55 (1.3) 2.12 (1.2) Young F, 2012 Goldhaber-Fiber JD, 2011 46 countries 337399 7956 2.12 (1.15) 1.55 (1.3) Cross-sectional (OR) Goldhaber-Fiber JD, 2011 46 countries 1.40 (10.0) 1.53 (1.4) Vang Q, 2013 China 13057 6382 3.77 (1.14) 1.70 (1.2) Case-control (OR) Texas Canterk 1.53 (0.81, 1.70 (1.2) 1.75 (1.3) Case-control (OR) Texas Canterk 1.53 (0.81, 1.70 (1.2) 1.75 (1.3) Case-control (OR) Texas Canterk 1.53 (1.31 (1.37, 1.75 (1.32, 1.75 (1.32) 1.77 (1.14) Pablics-Marridz Lapsen D, 2011 Tanzania 6.03 300 0 2.38 (1.05 (1.13) 1.53 (1.13 (1.75 (1.32) Lar SW, 2014 Tanzania					-		3.07 (1.14,
Debler CC, 2012 Australia 19855233 6276 Denow SE, 2015 USA 2797000 6050 Lee CH, 2013 Taiwan 70782 1228 Young F, 2012 Expland 837399 7996 Pooled estimate (I-squared = 77.1%, p = 0.000) 124545 1744 Arkris SM, 2011 USA 124545 1744 Marks SM, 2011 USA 190306 668 Vang F, 2012 Chana 13057 6382 Pooled estimate (I-squared = 28.9%, p = 0.245) 1.70 (1.27) 1.70 (1.27) Case-control (OR) Teams Centrols 1.83 (137, 11.4 Aligiphona B, 2005 Indonesia 454 556 Cortex R, 2006 Russia 344 347 Preez A, 2006 Russia 343 340 LargeN, 2011 Tanzania 803 300 LargeN, 2014 Taiwan 2456 14274 Centrol V, 2012 USA 166 15191 Jarce-Spricoric A, 2013 Cortalia 30					10000	-	1.76 (0.54,
Demiow SE, 2015 USA 27797000 6050 Lee (H. 2013 Taiwan 70782 1228 Young F., 2012 England 837399 7996 Probled estimate (I-squared = 77.1%, p = 0.000) Cross-sectional (OR) Golinaber-Fibert JD., 2011 46 countries 124545 1744 Marks SM, 2011 USA 190350 668 Wang Q., 2013 China 13057 6382 Palice-Merdiz A., 2014 USA 5290 37366 Alsgishtma B., 2006 Indonesia 454 556 Corker R., 2006 Russia 334 334 Preiz A., 2014 USA 5290 37366 Alsgishtma B., 2006 Indonesia 454 556 Corker R., 2006 Russia 334 334 Preiz A., 2011 USA 3847 66714 Fautrol-Lepsen D., 2011 Tanzania 603 350 Caker R., 2015 Republic of Kinbasi 275 499 Buskn SE, 1994 USA 151 545 Ku NS, 2013 Drotatia 300 300 Lai SW., 2014 Taiwan 11366 45464 Viney K., 2015 Republic of Kinbasi 275 499 Buskn SE, 1994 USA 151 545 Ku NS, 2013 Job USA 346 456 Vuney K., 2015 Republic of Kinbasi 275 499 Buskn SE, 1994 USA 151 545 Ku NS, 2013 Drotatia 300 300 Ku NS, 2013 Drotatia 200 USA 346 456 Vuney K., 2015 Republic of Kinbasi 275 499 Buskn SE, 1994 USA 151 545 Ku NS, 2013 USA 346 454 Vuney L., 2015 Republic of Kinbasi 275 499 South Korea 170 340 Ku NS, 2013 Drotatia 200 USA 346 468 Vu HP, 2006 USA 448 220 Rotationa 224 438 Pooled estimate (I-squared = 79.5%, p = 0.000)					-	i i	1.00 (0.69,
Lie CH, 2013 Taiwan 70782 1228 Young F, 2012 England 837399 7996 Pooled estimate (I-squared = 77.1%, p = 0.000) Cross-sectional (OR) Galdhaber-Fabert JD, 2011 46 countries 124545 1744 Marks SM, 2011 USA 190350 668 Pooled estimate (I-squared = 28.9%, p = 0.245) Case-control (OR) Pablos-Mendez A, 2014 USA 5290 37366 Alighabhan B, 2005 Indonesia 454 556 Cortes V, 2012 USA 186 15191 Jarcev-Savicevic A, 2013 Cinata 303 300 Cortes V, 2012 USA 186 15191 Jarcev-Savicevic A, 2014 Taiwan 11366 4564 Virey K, 2015 Republic of Kinbas 275 499 Buskn SE, 1994 USA 148 290 Mor MA, 1992 USA 46 46 Pooled estimate (I-squared = 79.5%, p = 0.000)						1000	
Young F, 2012 England 837399 7996 Pooled estimate (I-squared = 77.1%, p = 0.000) 2.02 (1.35, 1.31) Cross-sectional (OR) Gdihaber-Fielderl, 0., 2011 46 countries 124545 Gdihaber-Fielderl, 0., 2011 USA 190350 668 Wang Q, 2013 China 13057 6382 Pablos-Mendez, A, 2014 USA 5290 37766. Altsjahbana B, 2005 Indonesia 454 558 Pablos-Mendez, A, 2014 USA 5390 37366. Altsjahbana B, 2005 Indonesia 454 554 Corker R, 2006 Russia 344 354 Corker R, 2006 Russia 350 1.33 (0.81, 1.37 (1.14), 1.37 (1.23), 1.37 (1.14), 1.37 (1.24), 1.37 (1.23), 1.37 (1.14						+	2.18 (1.79,
Pooled estimate (I-squared = 77.1%, p = 0.000) 1.55 (1.3) Cross-sectional (OR) 1.55 (1.3) Goldbaber-Fiber JD, 2011 46 countries 124545 Marks SM, 2011 USA 190350 688 Vandage JD, 2013 China 13057 6382 Pooled estimate (I-squared = 28.9%, p = 0.245) 1724 1.40 (100, 377 (1.14, 776 (1.12)) Case-control (OR) Taraxes Centrols 1.70 (1.12) Case-control (OR) Taraxes Centrols, 7366 1.73 (1.14, 776 (1.22)) Case-control (OR) Taraxeis Centrols, 73766 1.73 (1.13, 776 (1.12)) Case-control (OR) Taraxeis Centrols, 73766 1.73 (1.13, 776 (1.12)) Cories V., 2015 Russia 3347 66714 1.78 (1.13) (1.13 (1.13)) Faurhol-Lepsen D., 2011 Taraxeis 2550 14274 1.18 (1.13, 1.18) (1.13) Cories V., 2012 USA 156 454 545 1.70 (0.70) Jarow Savcorica A., 2013 Taraxeis 275 499 2.88 (0.23) 1.58 (0.23) 1.58 (0.23) 1.58 (0.23)					+		
Cross-sectional (OR) Goldhaber-Fiebert JD., 2011 46 countries 124545 1744 1.81 (137, 140 (100, 140 (110, 140 (100, 140 (110, 140 (100, 140 (110, 140, 140 (110, 140 (110, 140, 140, 140, 140 (110, 140			837399	7996	1.1	←	
Goldhaber-Feberl JD, 2011 46 countries 124545 1744 Marks SM, 2011 USA 190350 668 Wang Q, 2013 China 13057 6382 Pooled estimate (I-squared = 28.9%, p = 0.245) 176 raws 1.40 (100) Case-control (OR) T8 cases Cantents Alloighthma B, 2006 Indonesia 454 556 Ocker R, 2006 USA 3847 66714 Alloighthma B, 2006 USA 3847 66714 Legashowlends A, 2011 Denmark 2960 14274 Coris V, 2012 USA 166 15191 Juncev-Savicevic A, 2013 Croatia 300 300 Lis SW, 2014 Taixan 366 36600 Viney K, NS, 2013 South Korea 170 1.50 (15.16) Researd P, 1994 USA 148 290 Juck SS, 2006 USA 448 290 Juck SS, 2006 USA 368 368000 W HP, 2007 Taiwan 264 438 <td>Pooled estimate (I-squared =</td> <td>77.1%, p = 0.000)</td> <td></td> <td></td> <td>0</td> <td>1</td> <td>1.55 (1.39</td>	Pooled estimate (I-squared =	77.1%, p = 0.000)			0	1	1.55 (1.39
Marks SM, 2011 USA 190350 668 Wang Q, 2013 Ohna 13057 6382 Vang Q, 2013 Ohna 13057 6382 Case-control (OR) Texes Casteria Pablos-Mendez A, 2014 USA 5290 37366 Alisphana B, 2006 Indonesia 454 556 Cocker R, 2006 USA 3347 166714 Pautos-Mendez A, 2011 Denmark 22950 14274 Coris V, 2012 USA 166 15191 Jurrow-Savonkic A, 2013 Dronatia 300 2381 (136 Lai SW, 2014 Tarixania 64564 15191 Jurrow-Savonkic A, 2015 Republic of Kinbai 275 499 Buskin SE, 1994 USA 151 545 Jark SS, 2006 USA 448 220 Rosesman KD, 1992 USA 454 438 Pooled estimate (I-squared = 79.5%, p = 0.000) 250 (122) 3.43 (216)	Cross-sectional (OR)				_		
Wang Q. 2013 China 13057 6382 Pooled estimate (I-squared = 28.9%, p = 0.245) 170 (1.2) Case-control (OR) Te cases Centrols Pabloe-Almodiz A, 2014 USA 5290 37366 Allajahbana B. 2006 Indonesia 454 Allajahbana B. 2006 USA 3847 Ferze A, 2011 Denmark 2950 14274 Leegaard A, 2011 Denmark 2950 14274 Leegaard A, 2011 Denmark 2950 14274 Las W., 2015 Republic-Kirbait 275 499 Buskin SE, 1994 USA 11366 45464 Viney K. 2013 South Korea 170 340 Roesmank KD, 1996 USA 148 290 Juck SS, 2006 USA 148 290 Mori MA, 1992 USA 46 Vin HP, 2007 Taiwan 264 338 Pooled estimate (I-squared = 79.5%, p = 0.000) 24 438	Goldhaber-Fiebert JD., 2011	46 countries	124545	1744	-	-	1.81 (1.37,
Pooled estimate (I-squared = 28.9%, p = 0.245) 1.70 (1.2) Case-control (OR) 18 cases Cannot (1.2) Algishbana B, 2006 Indonesia 454 556 Algishbana B, 2006 Indonesia 334 334 Prez A, 2006 Russia 334 334 Prez A, 2006 Russia 3347 66714 Fautrol-kopsen D, 2011 Tanzania 803 350 Corris V, 2012 USA 166 15191 Juroen-Savicevic A, 2013 Croatia 300 238 (10.5) Lai SW, 2014 Taiwan 11366 45464 Viney K, 2015 Republic of Kinbasi 275 499 Buskin SE, 1994 USA 151 545 Statistic S, 2006 UK 497 1966 Win P, 2007 USA 46 46 Viney K, 2015 Republic of Kinbasi 275 499 Backin SE, 1994 USA 340 153 (0.75, 150 (11.5) Roseman KD, 1996 USA 346 260 <td>Marks SM., 2011</td> <td>USA</td> <td>190350</td> <td>668</td> <td>+</td> <td>20</td> <td>1.40 (1.00,</td>	Marks SM., 2011	USA	190350	668	+	20	1.40 (1.00,
Case-control (OR) 19 cases Castrol Pablos-Mendez A, 2014 USA 5290 37366 Majabhana B, 2006 notonesia 454 556 Caser, 2008 Russia 334 334 Perez A, 2008 USA 3347 66714 Tanzania 803 300 12731 Leegaard A, 2011 Denmark 2950 14274 Corist V, 2012 USA 166 15191 Jurcen-Saviceric A, 2013 Creatia 300 300 Jurcen-Saviceric A, 2014 Taixania 300 300 Jurcen-Saviceric A, 2015 Republic of Kinbas 275 499 Uskn SE, 2066 UK 497 1966 1.50 (12.5) Juick SS, 2066 USA 148 290 1.50 (20.0) Julk SS, 2066 USA 148 290 1.50 (11.5) Researd P, 2006 USA 368 6600 1.50 (11.5) Mort MA, 1992 USA 46 46 6	Wang Q., 2013	China	13057	6382			3.17 (1.14,
Caser-Control (CHV) USA 5290 37366 Allsjahbandendez, A. 2014 USA 5290 37366 Allsjahbande, A. 2005 Russia 334 334 Jaligahbande, A. 2006 Russia 334 334 Jeruhot-Lepsen D, 2011 Tarxania 803 350 Leegaard A, 2011 Denmark 2960 14274 Corris V. 2012 USA 166 15191 Jurow-Savicevic A, 2013 Croatia 300 2.38 (13.6) Jarwa-Savicevic A, 2015 Republic of Kinbait 275 499 Buskin SE, 1994 USA 151 545 Lick SS. 2006 UK 447 1966 Ku NS, 2013 South Korea 170 340 Brassard P. 2006 USA 386 38600 Vu HP. 2007 USA 45 4 Vu HP. 2007 Talwan 2264 438 Poeled estimate (I-squared = 79.5%, p = 0.000) 209 (1.7) 2.09 (1.7)	Pooled estimate (I-squared =	28.9%, p = 0.245)			<	>	1.70 (1.28
Pablos-Mendez A. 2014 USA 5290 37386 Majshbna B., 2006 Indonesia 454 556 Coker R., 2006 Russia 334 334 Perez A. 2006 USA 3347 66714 Faurboh-kepsen D., 2011 Tanzania 803 350 Leegaard A., 2015 Demmark 2550 14274 Lars W., 2011 Tanzania 300 300 Jurcen-Sarloenic A., 2013 Croatia 300 300 Jurcen-Sarloenic A., 2015 Republic of Kinbas 275 439 Diskrin SE, 2066 USA 151 545 Julk SS, 2066 USA 148 290 Julk SS, 2066 USA 486 46 Vul HP, 2007 Tawan 264 438 Pooled estimatie (I-squared = 79.5%, p = 0.000) 200 2.09 (1.7	Case-control (OR)		TB cases	Controls			
Alisjabhana B, 2006 Indonesia 454 556 Colare R, 2006 Russia 334 334 Perez A, 2006 USA 3847 66714 Faurbol-Lepsen D, 2011 Tanzania 803 350 Legaard A, 2011 Demmark 2550 14274 Loegaard A, 2011 USA 166 15191 Jurow-Savicovic A, 2013 Croatia 300 238 (11.5) Lai SW, 2014 Tativan 11366 45464 Viney K, 2015 Republic of Kinbati 275 499 Buskin SE, 1994 USA 151 545 Lick SS, 2006 UK 497 1966 Ku NS, 2013 South Korea 170 340 Rosemman KD, 1996 USA 148 230 Rosemmar KD, 1996 USA 436 45 Vu H-P, 2007 USA 45 438 Pooled estimate (I-squared = 79.5%, p = 0.000) 204 438		USA	5290	37366			1.53 (0.81.
Coker R, 2006 Russia 334 334 334 Preze A, 2006 USA 3347 66714 175 [12 37 Faurboh-Legsand A, 2011 Tanzania 803 350 213 [137 Leegaard A, 2011 Denmark 2950 14274 18 [8 0,66 Coris V, 2012 USA 186 15191 231 [136 Jarcon-Sandonic A, 2013 Croatia 300 300 238 [105 Jarkon-Sandonic A, 2013 Croatia 300 300 238 [105 Jark SN, 2014 Taiwan 11366 45464 1.46 [138] 208 [2.00 Juk SS, 2006 USA 151 545 1.70 [0.77] 300 [2.30 Juk SS, 2006 USA 148 290 1.6 [0.58] 1.6 [0.58] Researd P, 2006 USA 368 366000 1.50 [1:5 [0.52] 1.50 [1:5 [0.52] Mort HA, 1992 USA 46 46 438 3.43 [2.0] [1.20] 3.43 [2.0] [1.20] Vu HP, 2007 Taiwan 264 438					1		4.70 (2.70.
Perez A. 2006 USA 3947 66714 175 [132] Leegaard A. 2011 Denmark 2950 14274 118 [0.96] Corris V. 2012 USA 166 15191 231 [132] Largware-Savoceric A. 2013 Croatia 300 300 Lat SW. 2014 Taiwan 11366 45464 146 [138] Uney K. 2015 Republic of Kinbas 275 499 Buskn SE, 1994 USA 151 545 248 [24] Lick SS. 2006 UK 497 1996 Brassard P. 2006 USA 386 38600 150 [150 [150 [150 [150 [150 [150 [15					_		
Faurbolt-Jespeen D., 2011 Tanzznia 803 350 2.13 (1.37) Leogaard A., 2011 Demmark 2550 14274 1.18 (0.96) Corris V., 2012 USA 166 15191 2.33 (1.36) Jurow-Savicowick, A.2013 Crostia 300 2.33 (1.36) Lai SW, 2014 Taiwan 11386 45464 1.46 (1.38) Viney K., 2015 Republic of Kinbasi 275 499 2.28 (1.05) Juck SS, 2006 USA 151 545 1.70 (0.70) Juck SS, 2006 USA 148 290 1.16 (0.56) Roseman KD, 1996 USA 148 290 1.16 (0.56) Roseman KD, 1906 USA 48 260 1.50 (1.15) Mori MA, 1992 USA 48 46 438 Pooled estimate (I-squared = 79.5%, p = 0.000) 2.09 (1.7) 2.09 (1.7)							1.75 (1.32,
Leegaard A, 2011 Denmark 2950 14274 118 (0.96) Corris V., 2012 USA 166 15191 Jurow-Savicedic A, 2013 Croatia 300 300 Lat SW, 2014 Taiwan 11366 45464 146 (1.38) Whey K, 2015 Republic of Kirbak 275 499 280 (200 Buskin SE, 1994 USA 151 545 200 Buskin SE, 1994 USA 151 545 300 Ku NS, 2013 South Korea 170 340 153 (0.75) Resemma RO, 1996 USA 386 38600 150 (1.50) (1.00	+	2.13 (1.37.
Corris V. 2012 USA 166 15191 2.31 (1.36) Jurow-Savicowick A.2013 Cronstia 300 2.38 (1.05) Lai SW. 2014 Taiwan 11386 45464 1.46 (1.38) Jurow-Savicowick Republic of Kinbati 275 499 2.28 (1.05) Buskin SE, 1994 USA 151 545 1.70 (0.70) Juck SS, 2006 USA 497 1966 1.53 (0.75) Roseman KD, 1996 USA 148 290 1.15 (0.15) Roseman KD, 1992 USA 486 466 1.50 (1.15) Worl HP, 2007 Taiwan 2264 2.30 (2.30) 1.50 (1.15) Pooled estimate (I-squared = 79.5%, p = 0.000) 264 438 2.09 (1.7)		Denmark	2950	14274	+		1.18 (0.96,
Juron-Savionic A, 2013 Cinatia 300 300 238 (1)5 Lai SW, 2014 Taiwan 11366 45464 1.46 (138) Viney K., 2015 Republic of Kiribati 275 499 280 (2)0 Buskn SE, 1994 USA 151 545 1.46 (133) Juros-Savionica SCO UK Viney K., 2015 Republic of Kiribati 275 499 280 (2)0 Buskn SE, 1994 USA 151 545 1.46 (133) 3.02 (230) Ku NS, 2013 South Korea 170 340 3.80 (230) 3.80 (230) Brassard P, 2006 USA 386 38600 1.16 (0.58) 520 (122) Mori IAL, 1992 USA 46 46 520 (122) 3.43 (2) (1.8) Vin HP, 2007 Taiwan 224 433 3.43 (2) (1.7) 2.09 (1.7)						+	2.31 (1.36,
Lai SW, 2014 Taiwan 11386 45464 1.46 (1.38 Viney K., 2015 Republic of Kinbasi 275 499 Buckh SE, 1994 USA 151 545 Novel K. 1996 USA 151 545 Roseman KD, 1996 USA 148 220 Taissard P., 2006 USA 346 36600 Mori NA, 1992 USA 46 46 Pooled estimate (I-squared = 79.5%, p = 0.000)	Jurcev-Savicevic A., 2013	Croatia	300	300		•	2.38 (1.05,
Viney K., 2015 Republic of Kinbati 275 499 280 (200 Buskin SE, 1994 USA 151 545 170 (070 Juck SS, 2006 UK 497 1996 3.80 (230 Ku NS, 2013 South Korea 170 340 1.51 (0.53 (0.75) Brassard P, 2006 USA 148 290 1.50 (0.75) Mori MA, 1992 USA 46 46 520 (122) Wu HP, 2007 Taiwan 264 438 3.43 (2.16) Pooled estimate (I-squared = 79.5%, p = 0.000) 2.09 (1.7) 2.09 (1.7)		Taiwan			٠	1	1.46 (1.38,
Jick SS, 2006 UK 497 1966 380 (2.30 Ku NS, 2013 South Korea 170 340 Brassard P, 2006 USA 148 290 1.16 (0.58 Brassard P, 2006 USA 386 36600 1.16 (0.57 Worl MA, 1992 USA 46 46 Wu HP, 2007 Taiwan 264 438 Pooled estimate (I-squared = 79.5%, p = 0.000)		Republic of Kiribati	275	499		+	2.80 (2.00,
Ku NS, 2013 South Korea 170 340 1.53 (0.75 Rosenman KD, 1996 USA 148 290 1.16 (0.85 Brassard P, 2006 USA 386 38800 1.50 (1.15 Mori MA, 1992 USA 45 46 520 (1.22 Vu HP, 2007 Talwan 224 438 3.43 (2.16) Pooled estimate (I-squared = 79.5%, p = 0.000) 2.09 (1.7) 2.09 (1.7)				545		A DOOR	1.70 (0.70,
Ku NS, 2013 South Korea 170 340 1.53 (0.75 Roseman KD, 1996 USA 148 290 1.16 (0.58 Brassard P, 2006 USA 386 38800 1.16 (0.58 Mori MA, 1992 USA 46 46 520 (1.22 Vu HP, 2007 Taiwan 264 438 3.34 (2.16) Pooled estimate (I-squared = 79.5%, p = 0.000) 2.09 (1.7) 2.09 (1.7)	Jick SS., 2006	UK	497	1966		-	3.80 (2.30,
Brassard P, 2006 USA 386 38600 Moi MA, 1992 USA 46 46 Vol HP, 2007 Talwan 264 438 Pooled estimate (I-squared = 79.5%, p = 0.000)		South Korea	170	340		- Part - P	1.53 (0.75,
Mori MA., 1992 USA 46 46 Wu HP., 2007 Taiwan 264 438 Pooled estimate (I-squared = 79.5%, p = 0.000) 2.09 (1.7					-+	1	1.16 (0.58,
Wu HP, 2007 Taiwan 264 438 3.43 (2.16) Pooled estimate (I-squared = 79.5%, p = 0.000) 2.09 (1.7)	Brassard P., 2006				-		1.50 (1.15,
Pooled estimate (I-squared = 79.5%, p = 0.000) 2.09 (1.7	Mori MA., 1992	USA			-		5.20 (1.22,
			264	438			3.43 (2.16,
Duarall project estimate (Leavared = 90.5%, n = 0.000)	Pooled estimate (I-squared =	79.5%, p = 0.000)				0	2.09 (1.7
	Overall nonled estimate (I.sn	uared = 90.5% n = 0	000)			4	2.00 (1.78,

The impact of diabetes on tuberculosis treatment outcomes: A systematic review

Meghan A Baker^{1,2}, Anthony D Harries^{3,4}, Christie Y Jeon^{5,10}, Jessica E Hart⁶, Anil Kapur⁷, Knut Lönnroth⁸, Salah-Eddine Ottmani⁸, Sunali D Goonesekera² and Megan B Murray^{2,9*}

	Relative risk	95% CI			
2-mth culture +	Highly variable; no summary statistics				
Failure or death	1.69	1.36 - 2.12			
Death	1.89	1.52 - 2.36			
Recurrence	3.89	2.43 - 6.23			

Baker et al, BMC Med 2011

Viral infections


- Associations with DM for many viruses
- Influenza
- Emerging respiratory viruses
- Arboviruses (Dengue, West-Nile, Chikungunya, Zika, JE, yellow fever..)
- More and more severe
- SARS: 3-fold higher mortality among DM
- MERS: DM in 68% of cases and 66% of deaths
- Dengue: lower platelets, more ICU, higher mortality
- Chikungunya: more and longer myalgia/arthralgia

Diabetes and COVID-19

COVID-19 and Diabetes

TABLE 1 Overview of the risk of adverse COVID-19-related outcomes in patients with type 1 and type 2 diabetes mellitus.

	Study population	Number of patients (n)	Outcome	T1D <i>vs</i> no DM OR (95% Cl)	T2D <i>vs</i> no DM OR (95% Cl)
Barron et al. (9)	United Kingdom, nationwide population-based <i>March 1st – May 11th 2020</i>	T1D: 263,830 T2D: 2,864,670 No DM: 58,244,220	Mortality	3.51 (3.16 – 3.90) [#] 2.86 (2.58 – 3.18) ^{\$}	2.03 (1.97 – 2.09) [#] 1.80 (1.75 – 1.86) ^{\$}
McGurnaghan et al. (50)	2	T1D: 34,383 T2D: 275,960 No DM: 5,143,951	Mortality and/or ICU admission	2.40 (1.82 – 3.16) ^{&}	1.37 (1.28 – 1.47) ^{&}
Gregory et al. (51, 52) $^{\Phi}$	Nashville, Tennessee, USA, single-center* <i>March 17th – December 24th 2020</i>	T1D: 136 T2D: 1,100 No DM: 19,422	Hospitalization	4.60 (3.04 – 6.98)€	3.42 (2.94 – 3.99) [€]



- English primary care data 2010-2015 (>85.000 DM patients, >150.000 controls)
- Consistently higher risk of infection compared to non-DM, higher risk with higher HbA1c
- 24% of TB among DM patients in UK is a result of poor glycemic control

Critchley J, Diabetes Care 2018


Conclusions 1

- Increase in diabetes prevalence worldwide
- Cardiovascular and other complications
- Infectious diseases
 - Higher risk (common, TB, viral, fungal, hospital-acquired...)
 - Worse outcome
- Highest risks associated with poor glycemic control

Contributing factors

- Host immunity
 - T-cells, B-cells, macrophages, neutrophils ...
- Neuropathy, microangiopathy, wound healing
- Obesity
- More *Staphylococcus aureus* carriage
- Glycosuria
- More health-care associated infections
 - More hospitalization, more instrumentation
- poor glycemic control:
 - more infections, more admissions, higher mortality

Anti-microbial host defense




Netea et al, Nature Immunol 2017

Immune cell populations in type 1 diabetes

	50FG	300DM	р
Size (<i>n</i>)	53	227	
WBC $(10^{9}/l)$	14.45 (11.33, 18.55)	14.54 (11.80, 18.32)	0.548
Neutrophils (10 ⁹ /l)	0.22 (0.12, 0.41)	0.15 (0.09, 0.26)	0.009
Neutrophils (%)	1.30 (0.85, 3.00)	1.00 (0.60, 1.80)	0.009
Lymphocytes (10 ⁹ /l)	10.43 (7.52, 13.08)	10.27 (8.22, 12.79)	0.77
Lymphocytes (%)	72.90 (65.25, 76.95)	72.20 (66.70, 77.10)	0.946
Monocytes (10 ⁹ /l)	3.36 (2.79, 4.36)	3.70 (2.80, 4.83)	0.285
Monocytes (%)	24.60 (20.40, 31.40)	25.70 (20.90, 30.80)	0.526
Eosinophils (10 ⁹ /l)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.739
Eosinophils (%)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.949
Basophiles (10 ⁹ /l)	0.12 (0.09, 0.21)	0.12 (0.08, 0.17)	0.707
Basophiles (%)	0.90 (0.60, 1.20)	0.80 (0.60, 1.20)	0.479

Neutrophil biological activities



Blanter et al, J Inflamm Res

 TABLE 1
 Studies investigating neutrophil chemotaxis in diabetes.

Study	Animal model/human volunteer type	Chemotaxis phenotypes reported in diabetes
Studie	s reporting a decrease in neutrophil chemotaxis in T1D or T2D co	mpared to control
(48)	HVs + T2D volunteers	↓ in chemotaxis towards casein and human serum
(117)	HVs + 17 children with T1D	t chemotaxis towards Staphylococcus epidermidis & albumin
(118)	HVs + those with T2D (mild to severe periodontitis)	No difference between HVs and those with mild periodontitis+T2D.
		Significant \downarrow in severe periodontitis + T2D.
		Endotoxin activated plasma and fMlp used as chemoattractant
(116)	Alloxan treated rat model	\downarrow in chemotaxis. Incubating healthy rat neutrophils in diabetic rat plasma also \downarrow
		chemotaxis
(119)	HVs+ volunteers with T1D	\downarrow chemotaxis towards zymosan-activated plasma. No difference towards fMlp and
		Escherichia coli supernatant
(49)	HVs + people with T1D and T2D	↓ chemotaxis towards fMlp but no difference towards healthy control serum
(55)	Akita mouse (point mutation in Ins2 gene- inability to produce insulin-	\downarrow chemotaxis towards fMlp and WKYMVm but no difference in random (unstimulated)
	T1D model)	migration.
(120)	Alloxan treated rats	No WT rats used in the study.
		\downarrow chemotaxis towards casein and fMLP in rats with severe compared to mild diabetes
(121)	Neutrophils investigated from WT rats incubated in serum from Alloxan	No difference in chemotaxis towards fMLP or Leukotriene B4.
	treated rats or WT	↓ chemotaxis towards LPS-activated rat sera in diabetic serum group
(122)	HVs + people with T2D undergoing tooth extractions	↓ chemotaxis towards fMLP
(51)	HVs + people with insulin dependent diabetes	↓ chemotaxis towards fMLP
(123)	Low dose STZ-treated mice	↓ chemotaxis towards casein

TABLE 2 | Studies Investigating Neutrophil ROS production in Diabetes.


Study	Animal model/human volunteer type	Changes in neutrophil ROS production reported in diabetes group compared to healthy control
Studie	s investigating neutrophil extracellular ROS production	
(54)	HVs + people with T2D	↑ in response to PMA and zymosan
(136)	HVs + people with T2D	↑ in response to PMA
		\downarrow in response to zymosan
(137)	HVs + PWD (does not specify type)	No difference in response to PMA
(138)	HVs + people with T1D	\uparrow in unstimulated neutrophils. \downarrow in response to fMLP and no difference when using PMA
(55)	Akita mouse (point mutation in Ins2 gene- inability to produce insulin-T1D model)	↑ in response to fMLP
(139)	HVs+ well controlled T1D	No difference in response to PMA
(140)	HVs+ volunteers with poor, moderate or well controlled T1D or T2D	↑ in response to fMLP in poorly controlled diabetes only (>8% HbA1c)
(123)	Low dose STZ-treated mice vs. WT	↓ in response to PMA
(141)	Healthy cats vs. diabetic cats (partial pancreatectomy)	↑ in response to PMA
(142)	HVs + patients with diabetes (T1D or T2D)	↑ in unstimulated neutrophils but decreased in response to PMA and zymosan
(143)	HVs + people with poorly controlled T2D	\downarrow in response to a mixture of zymosan, phorbol and NaF
(144)	HVs + patients with odontogenic bacterial infections or oral candidiasis with or without diabetes	↓ in response to PMA
(59)	HVs+ people with T1D or T2D with and without varying severities of periodontitis	↑ ROS in response to PMA and fMLP in participants with moderate (7-8%) or poor (>8%) glucose control
(145)	HVs + people with DFD	↓ in ROS in response fMLP. G-CSF increased ROS.
Studie	s investigating neutrophil intracellular ROS production	
(122)	HVs + people with T2D undergoing tooth extractions	↓ in ROS (stimulus not reported)
(146)	HVs + people with T2D and varying stages of diabetic nephropathy	↑ ROS. Greatest increase in patients with stage 4 nephropathy. (Multiple stimuli employed)
(147)	Newly diagnosed T1D patients not yet undergoing insulin therapy, T1D patients with disease duration of >3 months and healthy controls	↓ in ROS in response to PMA (greatest decrease in patients without insulin therapy)
(148)	HVs + people with T1D or T2D	↓ in ROS in response to PMA. Tolrestat increased ROS
(149)	HVs + infection free people with poorly controlled T2D (HbA1C <7.5%)	↓ in ROS in response to PMA
(126)	HVs + people with T2D and periodontitis	No difference in response to PMA. \downarrow in response to zymosan
(150)	STZ-treated rats v.s WT rats	↑ ROS at basal level (no stimulus used)
(125)	HVs + people with diabetes and periodontal disease	No difference in response to PMA. \downarrow in response to zymosan
(49)	HVs + People with T1D or T2D	No difference in response to PMA
(151)	HVs + people with T1D or T2D	\downarrow in response to endotoxin activated plasma
(141)	Healthy cats & diabetic cats (partial pancreatectomy)	No difference in response to PMA

Dowey et al, Front Immunol 2021

 TABLE 3 | Studies investigating neutrophil phagocytosis in diabetes.


(258) HVs + (50) Alloxa	orting a decrease in neutrophil phagocytosis in diabetes compared to control	
(50) Alloxa		
	+ peoplewith T2D	↓ in phagocytosis of <i>S. aureus</i> - only acidotic diabetic group,
(, , , , , , , , , , , , , , , , , , ,		no difference in people with non-acidotic diabetes
(259) HV/s J	an treated rat model	↓ in phagocytosis of <i>Streptococcus pneumoniae</i>
(200) 1100 1	+ children with T1D	↓ in phagocytosis
(260) HVs +	+ T2D	↓ in phagocytosis of <i>S. aureus</i> but no difference in
		phagocytosis of S. epidermidis
(261) HVs +	+ people with T2D	↓ in phagocytosis of <i>Burkholderia pseudomallei</i>
(262) Alloxa	an and diet induced diabetic mice	↓ in phagocytosis of LPS-coated fluorescent beads
(190) Alloxa	an treated rats- peritoneal neutrophils	1 in phagocytosis of opsonised Candida albicans
(65) Abdo	ominal sepsis model in diabetic diet induced mice	↓ in phagocytosis of <i>Escherichia coli</i>
(263) HVs +	+ people with T2D and poorly controlled blood glucose (>120 mg/dL)	↓ in phagocytosis of oil droplets containing oil red O, coated with <i>E. coli</i> derived LPS
(264) HVs +	+ people with T2D	↓ in phagocytosis of opsonised oil droplets containing oil red O, coated with <i>E. coli</i> derived LPS
(123) Low o	dose STZ-treated mice	↓ in phagocytosis of zymosan
(265) WT m	nice v.s db/db mice	1 in phagocytosis of pHrodo Red S. aureus Bioparticles
		Conjugate
(150) STZ-t	treated rats v.s WT rats	↓ in phagocytosis of opsonised and unopsonised
		Saccharomyces cerevisiae
(147) Newly	y diagnosed T1D patients not yet on insulin therapy, T1D patients with disease duration of	↓ in phagocytosis of <i>E. coli</i> (greatest decrease in new
	onths and healthy controls	diagnosed patients, not undergoing insulin therapy)
(122) HVs +	+ people with T2D undergoing tooth extractions	1 in phagocytosis of FITC- labelled opsonised E.coli
(266) HVs +	+ people with diabetes controlled with insulin	↓ in phagocytosis <i>Candida guilliermondii</i>
(139) HVs +	+ people with well-controlled T1D	↓ in phagocytosis <i>Candida albicans</i>
	+ people with T2D	↓ in phagocytosis- only in K1/K2 Klebsiella pneumoniae no
		difference in non-K1/K2 serotypes
(151) HVs +	+ people with T1D or T2D	1 in phagocytosis of heat killed opsonised Candida albicans
	+ people with T1D or T2D all receiving insulin	↓ in phagocytosis of <i>S. aureus</i>
	+ patients with odontogenic bacterial infections or oral candidiasis with or without diabetes	↓ in phagocytosis of latex particles

Dowey et al, Front Immunol 2021




Dowey et al, Front Immunol 2021

Monocyte cell function in diabetes




Janssen et al, Metabolism 2021

T-helper cell function in diabetes




Janssen et al, Metabolism 2021

IL-18 is crucial for IFN γ production




Umetsu et al, Nature Immunol

IL-18 in diabetes patients




Zilverschoon et al, Int J Obesity

IL-18 resistance in diabetes patients




IFN γ production in diabetes patients is defective




Zilverschoon et al, Int J Obesity

IFN γ production in diabetes patients is IL-18 dependent




Zilverschoon et al, Int J Obesity

Inflammation in diabetes patients




Tsalamandris et al, Int Soc Cardiovasc Pharm

Long-term epigenetic reprogramming in myeloid cells




Bone marrow-derived macrophages maintain hyperglycemic memory



Edgar et al, Circulation 2021

Bone marrow-derived macrophages from diabetic mice drive atherosclerosis



Edgar et al, Circulation 2021

Conclusions 2

- Diabetes patients present both increased susceptibility to infections and increased vascular complications
- Immune cells of diabetes patients display a defective response to pathogens
 - Decreased neutrophil and monocyte function
 - Defective IFNg responses due to IL-18 resistance
- At the same time, diabetes patients show inappropriate systemic inflammation
 - Role of epigenetic and functional changes due to hyperglycemia in myeloid cells and their progenitors in the bone marrow

Thank you !

Department of Internal Medicine-RadboudUMC

Siroon Bekkering Rinke Stienstra Jorge Dominguez Simone Moorlag Rob Arts Jos W.M. van der Meer Reinout van Crevel Leo Joosten Niels Riksen Cees Tack

Dept. Molecular Biology – Radboud University

Boris Novakovic Joost Martens Colin Logie Henk Stunnenberg

Dresden University

Ioannis Mitroulis Triantafyllos Chavakis **University of Oxford**

Laurienne Edgar Robin Choudhury

Mount Sinai New York / TUe

Willem Mulder Zahi Fayad Jordi Ochando

Athens University Evangelos Giamarellos

Bonn University - LIMES

Katarzyna Placek Eicke Latz Andreas Schlitzer Joachim Schultze